-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to relevant national policies, drug varieties that have passed the consistency evaluation of generic drugs will receive greater support in the fields of medical insurance payment and procurement by medical institutio.
In recent years, pharmaceutical companies have actively promoted the consistency evaluation of generic drugs, and have achieved continuous gai.
On May 30, another batch of pharmaceutical companies announced the good ne.
Let's take a look at which varieties have been reviewed! Warner Br.
announced that the company's pantoprazole sodium enteric-coated tablets passed the consistency evaluation of generic dru.
This variety belongs to the third generation of new proton pump inhibitors, mainly used to treat duodenal ulcer, gastric ulcer, moderate and severe reflux esophagitis, and clarithromycin and amoxicillin, or clarithromycin and metronidazole azole, or amoxicillin and metronidazole can eradicate Helicobacter pylori infecti.
Lukang Pharmaceutical announced that its cefoxitin sodium for injection has passed the consistency evaluation of generic dru.
Cefoxitin sodium is mainly used to treat infections caused by pathogenic bacteria sensitive to this product, especially for mixed aerobic and anaerobic infections and infections caused by β-lactamase-sensitive bacteria to this produ.
The announcement is bright r.
Since the consistency evaluation of the drug has been carried out, the company has invested about 2211 million yuan in research and development (unaudite.
The data shows that the sales of cefoxitin sodium for injection in domestic sample hospitals in 2021 will be RMB 246 million, of which the sales of this product of Lukang Pharmaceutical are about RMB 2 milli.
Fu'an Pharmaceutical announced in the evening that Ningbo Tianheng, a wholly-owned subsidiary of the company, recently received a notice of approval for a supplemental drug application issued by the State Food and Drug Administrati.
Reviewed revie.
Up to now, apart from the original researcher Novartis, the only manufacturer of baclofen tablets that has passed or is deemed to pass the consistency evaluation is Tianheng Pharmaceutic.
Data show that baclofen tablets are suitable for severe but reversible muscle spasms caused by multiple scleros.
and may have some curative effect on spasticity caused by infectious, degenerative, traumatic, neoplastic, or unexplained spinal cord diseas.
According to data from Min.
com, the sales of baclofen in 2021 will reach 264 million yuan, a year-on-year increase of 5
From the perspective of market share, Novartis occupies the majority of the market sha.
The industry believes that Ningbo Tianheng has won the first revi.
, the future market pattern may chan.
On the same day, Lingkang Pharmaceutical also announced that its wholly-owned subsidiary Lingkang Pharmaceutical's cefmetazole sodium for injection and pantoprazole sodium for injection have recently passed the quality and efficacy consistency evaluation of generic dru.
Among them, cefmetazole sodium for injection is mainly used for: the treatment of Cefmetazole sodium-sensitive Staphylococcus aureus, Escherichia coli, Pneumococcus, Proteus, Morganella morganii, Providence, Infections caused by Peptostreptococcus, Bacteroides, Prevotella (except dual Prevot vaccine): sepsis; acute bronchitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory disease ; cystitis, pyelonephritis; peritonitis; cholecystitis, cholangitis; bartholinitis, intrauterine infection, adnexitis, parametritis; perimaxillary cellulitis, jaw inflammati.
Pantoprazole sodium for injection is a proton pump inhibitor, which is mainly used to treat acute upper gastrointestinal bleeding such as duodenal ulcer, gastric ulcer, acute gastric mucosal lesions, and complex gastric ulc.
According to data from Min.
com, the sales of pantoprazole sodium for injection in 2021 will total about 196 billion yuan in urban public hospitals across the count.
In addition, according to the CDE website, companies that have passed/deemed to pass the consistency evaluation for this variety include Luye, Hengsheng Pharmaceutical, Zhongmei Huadong, and Sinopharm Mode.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
In recent years, pharmaceutical companies have actively promoted the consistency evaluation of generic drugs, and have achieved continuous gai.
On May 30, another batch of pharmaceutical companies announced the good ne.
Let's take a look at which varieties have been reviewed! Warner Br.
announced that the company's pantoprazole sodium enteric-coated tablets passed the consistency evaluation of generic dru.
This variety belongs to the third generation of new proton pump inhibitors, mainly used to treat duodenal ulcer, gastric ulcer, moderate and severe reflux esophagitis, and clarithromycin and amoxicillin, or clarithromycin and metronidazole azole, or amoxicillin and metronidazole can eradicate Helicobacter pylori infecti.
Lukang Pharmaceutical announced that its cefoxitin sodium for injection has passed the consistency evaluation of generic dru.
Cefoxitin sodium is mainly used to treat infections caused by pathogenic bacteria sensitive to this product, especially for mixed aerobic and anaerobic infections and infections caused by β-lactamase-sensitive bacteria to this produ.
The announcement is bright r.
Since the consistency evaluation of the drug has been carried out, the company has invested about 2211 million yuan in research and development (unaudite.
The data shows that the sales of cefoxitin sodium for injection in domestic sample hospitals in 2021 will be RMB 246 million, of which the sales of this product of Lukang Pharmaceutical are about RMB 2 milli.
Fu'an Pharmaceutical announced in the evening that Ningbo Tianheng, a wholly-owned subsidiary of the company, recently received a notice of approval for a supplemental drug application issued by the State Food and Drug Administrati.
Reviewed revie.
Up to now, apart from the original researcher Novartis, the only manufacturer of baclofen tablets that has passed or is deemed to pass the consistency evaluation is Tianheng Pharmaceutic.
Data show that baclofen tablets are suitable for severe but reversible muscle spasms caused by multiple scleros.
and may have some curative effect on spasticity caused by infectious, degenerative, traumatic, neoplastic, or unexplained spinal cord diseas.
According to data from Min.
com, the sales of baclofen in 2021 will reach 264 million yuan, a year-on-year increase of 5
From the perspective of market share, Novartis occupies the majority of the market sha.
The industry believes that Ningbo Tianheng has won the first revi.
, the future market pattern may chan.
On the same day, Lingkang Pharmaceutical also announced that its wholly-owned subsidiary Lingkang Pharmaceutical's cefmetazole sodium for injection and pantoprazole sodium for injection have recently passed the quality and efficacy consistency evaluation of generic dru.
Among them, cefmetazole sodium for injection is mainly used for: the treatment of Cefmetazole sodium-sensitive Staphylococcus aureus, Escherichia coli, Pneumococcus, Proteus, Morganella morganii, Providence, Infections caused by Peptostreptococcus, Bacteroides, Prevotella (except dual Prevot vaccine): sepsis; acute bronchitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory disease ; cystitis, pyelonephritis; peritonitis; cholecystitis, cholangitis; bartholinitis, intrauterine infection, adnexitis, parametritis; perimaxillary cellulitis, jaw inflammati.
Pantoprazole sodium for injection is a proton pump inhibitor, which is mainly used to treat acute upper gastrointestinal bleeding such as duodenal ulcer, gastric ulcer, acute gastric mucosal lesions, and complex gastric ulc.
According to data from Min.
com, the sales of pantoprazole sodium for injection in 2021 will total about 196 billion yuan in urban public hospitals across the count.
In addition, according to the CDE website, companies that have passed/deemed to pass the consistency evaluation for this variety include Luye, Hengsheng Pharmaceutical, Zhongmei Huadong, and Sinopharm Mode.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
